Robust immune response from AstraZeneca’s COVID-19 drug

By: Miguel A. Rodriguez

12:40, 23 November 2020

AstraZeneca joins Moderna and Pfizer in combating COVID-19

The race for finding a viable COVID-19 vaccine intensified in the past couple of weeks. After Moderna and Pfizer announced that their experimental COVID-19 vaccines have over 90% effectiveness in preventing the infection, another company reported impressive results.

AstraZeneca stated that according to the early-stage trials, its vaccine triggers an immune response among adults. The data collected from 560 volunteers revealed that the adults aged between 18 and 55 and those over 56 had a similar immune response.

“We’re really delighted with the results,” stated Professor Andrew Pollard, Head of Oxford’s vaccine trial team.  The vaccine - ChAdOx1 nCoV-19 showed a response 14 days after the first administrated dose, while antibodies appeared 28 days after the second dose, which is considered a booster.

As stated before, other pharma companies announced their vaccines’ effectiveness. Pfizer, whose vaccine is 95% effective in preventing COVID-19 infection, is said to file for an emergency use application to the FDA later today. Moderna is expected to do the same in the following days.

In pre-market trading, AstraZeneca stock price gained 1.80%.

Read here and here about Moderna and Pfizer’s vaccines!


Share this article

This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.